Welcome to our dedicated page for Stereotaxis Ord news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis Ord stock.
Stereotaxis, Inc. (NYSE: STXS) is active in surgical robotics and medical device innovation, and its news flow reflects ongoing developments in minimally invasive endovascular intervention and cardiac electrophysiology. Company announcements frequently highlight regulatory milestones, product clearances, clinical adoption, and capital markets activity, making the STXS news page a focused resource for tracking these events in one place.
Recent news releases describe U.S. Food and Drug Administration approval of the MAGiC Magnetic Interventional Ablation Catheter, FDA 510(k) clearance for the GenesisX Robotic Magnetic Navigation system, and CE Mark in Europe for the Synchrony digital cath lab system along with a 510(k) submission to the FDA. Other updates cover the commercial launch and first procedures using the MAGiC Sweep high-density electrophysiology mapping catheter, as well as clinical use of the Genesis system at leading medical centers.
Investors and clinicians following STXS can also find news on collaborations, such as the agreement with CardioFocus to advance a robotic pulsed field ablation solution for cardiac arrhythmias. Financial and investor-relations updates, including quarterly earnings press releases and participation in healthcare and growth conferences, are regularly communicated through company news.
This page aggregates these categories of information—regulatory clearances, product launches, clinical milestones, collaborations, and financial communications—so readers can monitor how Stereotaxis’ robotic systems, catheters, and digital cath lab technologies progress over time. For anyone tracking STXS stock or the evolution of its technology portfolio, the news feed offers a structured view of the company’s publicly reported developments.
Stereotaxis (NYSE: STXS) announced the first United States patients treated with MAGiC™, its robotically-navigated magnetic ablation catheter, following FDA PMA approval on April 22, 2026. The initial U.S. case, performed by Dr. Nathan McConkey, treated complex congenital heart disease via basilic vein access with no recurrence in the weeks after the procedure. MAGiC is indicated for mapping, pacing, and creating endocardial lesions to treat supraventricular tachycardias in congenital heart disease patients with limited conventional access.
The release highlights improved catheter stability, contact force, and energy delivery and positions MAGiC to expand minimally invasive ablation options for challenging anatomy.
Stereotaxis (NYSE: STXS) will report its first quarter 2026 financial results after U.S. market close on Tuesday, May 12, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss results and corporate developments.
Dial-in numbers and a live/replay webcast will be available via the company’s investor relations website; a phone replay will be accessible for one month beginning about four hours after the call.
Stereotaxis (NYSE: STXS) announced a definitive agreement to acquire Robocath on April 15, 2026, combining magnetic navigation and mechanical robotics to target electrophysiology, interventional cardiology and neurointerventions.
The deal includes an upfront payment of $20 million, contingent payments up to $25 million, expected mid-2026 close, and estimated $2 million first-year revenue with breakeven by year three.
Stereotaxis (NYSE: STXS) announced FDA 510(k) clearance and commercial launch of the Synchrony system on April 6, 2026. Synchrony is a 55" 4K interventional lab display with ultra-low latency video, obsolescence protection, and cloud-based SynX for HIPAA/GDPR-compliant remote collaboration.
The company reiterated guidance of over $3 million in 2026 revenue from Synchrony placements independent of robotic systems and emphasized future AI-enabled applications and broader cath lab adoption.
Stereotaxis (NYSE: STXS) reported 2025 results: revenue $32.4M (up 20% YoY) and Q4 revenue $8.6M (up 36% YoY). Recurring revenue was $22.2M (up 21%) and system revenue $10.2M (up 18%). Gross margin was ~53% for full year; cash was $13.4M with no debt.
Company highlighted US and EU approvals for GenesisX, MAGiC, and MAGiC Sweep and provided 2026 guidance targeting >$40M revenue and double-digit growth.
Stereotaxis (NYSE: STXS) will release fourth quarter and full year 2025 financial results on Monday, March 9, 2026 after U.S. market close and host a conference call and webcast at 4:30 p.m. ET.
Investors can dial in using U.S./Canada number 800-715-9871 or international 646-307-1963 with pass code 8365695, and a webcast and one-month phone replay will be available via the company investor relations site.
Stereotaxis (NYSE: STXS) announced a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany, making it the first hospital in Germany to adopt the Genesis Robotic Magnetic Navigation System for arrhythmia care. Physicians have treated initial patients across a range of arrhythmias using the system.
Company executives and Klinikum Fürth clinicians highlighted improved precision, procedural stability, and reduced radiation exposure from less fluoroscopic confirmation. Stereotaxis noted its technology has been used in over 150,000 patients globally and said it will support the hospital's robotic heart rhythm practice.
Stereotaxis (NYSE: STXS) announced FDA approval on January 6, 2026 of the MAGiC™ Magnetic Interventional Ablation Catheter for robotic cardiac electrophysiology procedures.
The MAGiC catheter is robotically navigated for mapping, diagnostic pacing, and creating endocardial lesions to treat supraventricular tachycardia in patients with congenital heart disease when conventional manual navigation is limited.
The company highlighted MAGiC's precision, expanded access for complex/underserved patients, and prior global use of Stereotaxis technology in over 150,000 patients.
Stereotaxis (NYSE: STXS) will participate in the Piper Sandler 37th Annual Healthcare Conference. David Fischel, chairman and CEO, will join a fireside discussion on December 3, 2025 at 9:00 AM ET and will be available for one-on-one investor meetings that day.
The release notes the company is achieving key regulatory milestones and showing early commercial growth. Stereotaxis develops robotic systems for minimally invasive endovascular intervention and reports its technology has been used to treat over 150,000 patients. The company included standard forward-looking risk disclosures about regulatory timing, market acceptance, and other business risks.
Stereotaxis (NYSE: STXS) reported results for the quarter ended September 30, 2025: total revenue $7.5M (Systems $1.9M; Recurring $5.6M). Gross margin was 55% (recurring 67%, systems 19%). Operating loss was $6.6M and net loss was $6.5M, with adjusted operating loss excl. non-cash charges of $2.5M. Negative free cash flow for Q3 was $4.2M. Cash on hand was $10.5M (pro forma $14.5M including an upcoming $4M financing tranche).
Operational highlights include FDA clearance for GenesisX, CE Mark and FDA submission for Synchrony, early commercial sales of MAGiC and MAGiC Sweep (>$300k revenue in first two months), and two Genesis orders in Europe. Company expects Q4 revenue >$9M and full-year 2025 revenue growth >20%.